Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Profit After Tax: 2017-2024

Historic Profit After Tax for Kiniksa Pharmaceuticals International (KNSA) over the last 8 years, with Dec 2024 value amounting to -$43.2 million.

  • Kiniksa Pharmaceuticals International's Profit After Tax rose 245.24% to $18.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.9 million, marking a year-over-year increase of 496.10%. This contributed to the annual value of -$43.2 million for FY2024, which is 406.68% down from last year.
  • According to the latest figures from FY2024, Kiniksa Pharmaceuticals International's Profit After Tax is -$43.2 million, which was down 406.68% from $14.1 million recorded in FY2023.
  • Kiniksa Pharmaceuticals International's 5-year Profit After Tax high stood at $183.4 million for FY2022, and its period low was -$161.4 million during FY2020.
  • Moreover, its 3-year median value for Profit After Tax was $14.1 million (2023), whereas its average is $51.4 million.
  • Per our database at Business Quant, Kiniksa Pharmaceuticals International's Profit After Tax soared by 216.11% in 2022 and then crashed by 406.68% in 2024.
  • Yearly analysis of 5 years shows Kiniksa Pharmaceuticals International's Profit After Tax stood at -$161.4 million in 2020, then rose by 2.14% to -$157.9 million in 2021, then surged by 216.11% to $183.4 million in 2022, then tumbled by 92.32% to $14.1 million in 2023, then plummeted by 406.68% to -$43.2 million in 2024.